STOCK TITAN

Portage Biotech Inc. - PRTG STOCK NEWS

Welcome to our dedicated page for Portage Biotech news (Ticker: PRTG), a resource for investors and traders seeking the latest updates and insights on Portage Biotech stock.

Portage Biotech Inc. (NASDAQ: PRTG) is a leading clinical-stage immuno-oncology company based in Canada. The company is dedicated to developing innovative therapies aimed at overcoming immune resistance in cancer patients. With a strong focus on unmet clinical needs, Portage Biotech is managing an impressive pipeline of 10 immuno-oncology assets at various stages of development.

Portage Biotech's key products include IMM-60, an invariant natural killer T cell (iNKT) engager, and PORT-6 and PORT-7, which are adenosine 2A (A2A) and adenosine 2B (A2B) inhibitors, respectively. These assets are being developed for various cancers, including non-small cell lung cancer (NSCLC) and advanced melanoma.

Notably, the company recently presented updates from its ongoing IMPORT-201 Phase 1/2 trial of PORT-2 (IMM-60) and its ADPORT-601 adaptive Phase 1a/1b trial for PORT-6 and PORT-7 at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting. The data shows promising results in safety and tolerability, as well as potential efficacy in combination therapies with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

Portage Biotech's unique business model leverages strong partnerships with academic experts and large pharmaceutical companies to rapidly advance multiple products efficiently. The company's commitment to patient-centric approaches and innovative trial designs aims to identify and target patient populations most likely to benefit from treatment. Despite challenges, including the decision to pause further drug development in the PORT-2 iNKT program due to funding constraints, Portage Biotech is focused on advancing its adenosine platform and continuing impactful clinical trials.

For the latest updates, financial results, and to learn more about ongoing and future projects, visit their official website.

Rhea-AI Summary

Portage Biotech Inc. (NASDAQ: PRTG) reported its financial results for FY 2022, with a net loss of approximately $19.2 million, up from $17.2 million in FY 2021. Operating expenses increased to $15.6 million, primarily driven by a rise in general and administrative costs. However, the company has bolstered its pipeline by acquiring four adenosine-targeting assets and extending its cash runway into 2024 through a $30 million share purchase agreement. Portage's promising clinical data, particularly for its PORT-2 study, signifies ongoing progress in immuno-oncology treatment development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Portage Biotech (PRTG) announced its FY 2022 financial results, reporting a net loss of approximately $19.2 million, up from $17.2 million in FY 2021. The company has recently enhanced its portfolio by acquiring four adenosine-targeting assets for about $21 million, potentially extending its cash runway into 2024 via a $30 million share purchase agreement. Despite a decrease in R&D costs to approximately $6.8 million, G&A expenses rose 73% to about $8.8 million. Portage's cash and cash equivalents as of June 30, 2022, were approximately $21 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Portage Biotech has acquired full ownership of iOx Therapeutics Ltd., obtaining the remaining 22% equity in exchange for 1,070,000 shares of Portage stock. This acquisition provides Portage complete rights to the iNKT agonist platform, including lead programs PORT-2 and PORT-3, which aim to enhance immune responses against solid tumors. A potential additional payment of $25 million in shares or cash is tied to a clinical milestone. Preliminary data from these programs is expected by early 2023, underlining Portage's commitment to advancing its immunotherapy portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
Rhea-AI Summary

Portage Biotech Inc. (PRTG) has acquired Tarus Therapeutics for approximately $21 million, gaining two clinical-stage and two preclinical adenosine compounds. This strategic move aims to enhance immuno-oncology treatments targeting the adenosine pathway, which is crucial in cancer treatment resistance. The deal involves the issuance of 2,425,999 shares and $3 million in liabilities. Additionally, a share purchase agreement with Lincoln Park Capital for up to $30 million is expected to extend Portage's cash runway into 2024. A conference call is scheduled for July 7, 2022, to discuss the acquisition and future plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
-
Rhea-AI Summary

Biohaven Pharmaceutical (NYSE: BHVN) and Vigeo Therapeutics announced their entry into the GBM AGILE trial, an adaptive platform study for glioblastoma treatments. This trial, which began in July 2019, aims to rapidly identify effective interventions for patients suffering from this aggressive brain cancer. Troriluzole and VT1021 will be tested in newly diagnosed and recurrent glioblastoma patients, with enrollment starting at Henry Ford Health in Detroit, expanding across over 40 sites in the US and globally. Overall, the trial seeks to optimize treatment outcomes through simultaneous testing of multiple therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
none
-
Rhea-AI Summary

Portage Biotech Inc. (NASDAQ: PRTG) shared preliminary data from its Phase 1/2 trial of PORT-2, an iNKT agonist for treating melanoma and NSCLC, at the 2022 ASCO meeting. The results indicate a favorable safety profile and tolerability as a monotherapy, with evidence of single-agent activity in heavily pre-treated patients. The company plans to evaluate PORT-2 further, both as a standalone treatment and in combination with pembrolizumab. In addition, ongoing collaborations with Intensity Therapeutics have shown promising results in various cancer trials, including neoadjuvant breast cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.47%
Tags
none
Rhea-AI Summary

Pfizer has announced its acquisition of Biohaven, the maker of NURTEC® ODT, for approximately $11.6 billion. Shareholders will receive $148.50 per share in cash and shares in a new company retaining Biohaven's non-CGRP assets. The acquisition enhances Pfizer's Internal Medicine pipeline, focusing on migraine treatments with high market potential. NURTEC is already the leading migraine therapy in the U.S. The deal includes the purchase of Biohaven's CGRP programs and is expected to close by early 2023, pending approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.72%
Tags
-
Rhea-AI Summary

Pfizer (NYSE: PFE) and Biohaven (NYSE: BHVN) announced the European Commission's marketing authorization for VYDURA® (rimegepant), the first medication approved for both acute and prophylactic treatment of migraines in adults. VYDURA® is an orally disintegrating tablet that targets a significant unmet need for migraine treatment in the EU, affecting around one in ten people. Clinical studies demonstrate its efficacy in reducing migraine symptoms and the frequency of attacks. The approval covers all 27 EU countries, with local reimbursement to follow.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.99%
Tags
none
-
Rhea-AI Summary

Portage Biotech Inc. (NASDAQ: PRTG) announced a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) and Stimunity, S.A.S to enhance cancer vaccine efficacy. The collaboration aims to develop STING agonists and anti-RAGE agents, leveraging the NCI’s resources for preclinical and potential clinical advancement. The STING pathway enables targeted immune response, while anti-RAGE agents may counteract immune suppression in cancer progression. Portage's innovative approach uses systemic delivery mechanisms to enhance vaccine effectiveness, with multiple clinical readouts expected in the next 12-24 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
Rhea-AI Summary

Portage Biotech Inc. (NASDAQ: PRTG) recently presented late-breaking preclinical data at the AACR 2022 Annual Meeting, highlighting the potential of PORT-5 (STI-001), a stimulator of interferon genes (STING) agonist. Data shows that this therapy, delivered via a virus-like particle, activates tumor-specific T cells and preferentially targets dendritic cells, enhancing anti-tumor responses. The study suggests that PORT-5 can be combined with other immunotherapies for improved efficacy against cancer, marking a significant advancement in the development of STING-based therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.95%
Tags
none

FAQ

What is the current stock price of Portage Biotech (PRTG)?

The current stock price of Portage Biotech (PRTG) is $5.19 as of December 24, 2024.

What is the market cap of Portage Biotech (PRTG)?

The market cap of Portage Biotech (PRTG) is approximately 5.8M.

What does Portage Biotech Inc. specialize in?

Portage Biotech Inc. specializes in developing immuno-oncology therapies to overcome immune resistance in cancer patients.

What are the key products in Portage Biotech's pipeline?

Key products include IMM-60 (iNKT engager), PORT-6 (A2A inhibitor), and PORT-7 (A2B inhibitor).

Where is Portage Biotech Inc. based?

Portage Biotech Inc. is based in Canada.

What recent clinical trials has Portage Biotech presented data from?

Portage Biotech presented data from the IMPORT-201 Phase 1/2 trial of PORT-2 and the ADPORT-601 adaptive Phase 1a/1b trial for PORT-6 and PORT-7.

What is the focus of the ADPORT-601 trial?

The ADPORT-601 trial focuses on evaluating adenosine 2A and 2B inhibitors in combination with other immunotherapies for solid tumors.

What partnerships does Portage Biotech leverage?

Portage Biotech leverages partnerships with academic experts and large pharmaceutical companies like Merck.

What decision did Portage Biotech make regarding the PORT-2 iNKT program?

Portage Biotech decided to pause further development in the PORT-2 iNKT program due to funding constraints.

What is the significance of Portage Biotech's business model?

Portage Biotech's business model enables rapid advancement of multiple products through strong academic and pharmaceutical partnerships.

How does Portage Biotech aim to improve patient outcomes?

By developing multi-targeted therapies and identifying patient populations most likely to benefit from their treatments.

Where can more information about Portage Biotech be found?

More information can be found on their official website at www.portagebiotech.com.

Portage Biotech Inc.

Nasdaq:PRTG

PRTG Rankings

PRTG Stock Data

5.82M
806.80k
29.81%
17.8%
0.96%
Biotechnology
Healthcare
Link
United States of America
Tortola